Literature DB >> 3146635

Tumor necrosis factor and HIV P24 antigen levels in serum of HIV-infected populations.

M M Reddy1, S J Sorrell, M Lange, M H Grieco.   

Abstract

Tumor necrosis factor (TNF) and HIV P24 antigen levels were determined in the serum of intravenous drug abusers (IVDAs), homosexuals, and patients with lymphadenopathy or acquired immune deficiency syndrome (AIDS). The mean TNF level in the serum of normal controls was 12 +/- 5 compared to 112 +/- 25 pg/ml in the serum of HIV-seronegative asymptomatic IVDAs. This increase of TNF may be due to the variety of infections that these people are exposed to persistently. The mean TNF level in the serum of HIV-seropositive asymptomatic IVDAs was 112 +/- 79 pg/ml, 31 +/- 24 pg/ml in lymphadenopathy, and 55 +/- 19 pg/ml in patients with AIDS. The mean P24 level in the serum of patients with AIDS was 50 +/- 13 pg/ml compared to 0 pg/ml in HIV-seronegative subjects, while the other HIV-seropositive groups had relatively low levels. The P24 antigen levels may reflect viral load in these patients. SIL-2R and beta2-microglobulin levels were also elevated in patients with HIV infection . The TNF may play a role in the antiviral activity against HIV virus and in the development of full-blown disease after HIV infection.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3146635

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr (1988)        ISSN: 0894-9255


  28 in total

Review 1.  Problems in pharmacokinetic investigations in patients with HIV infection.

Authors:  J D Unadkat; J M Agosti
Journal:  Clin Pharmacokinet       Date:  1990-09       Impact factor: 6.447

2.  Vpr Enhances Tumor Necrosis Factor Production by HIV-1-Infected T Cells.

Authors:  Ferdinand Roesch; Léa Richard; Réjane Rua; Françoise Porrot; Nicoletta Casartelli; Olivier Schwartz
Journal:  J Virol       Date:  2015-09-23       Impact factor: 5.103

3.  Casp8p41 expression in primary T cells induces a proinflammatory response.

Authors:  Julie A Taylor; Nathan W Cummins; Gary D Bren; Stacey A Rizza; Christopher P Kolbert; Marshall D Behrens; Keith L Knutson; Jane C Kahl; Yan W Asmann; Andrew D Badley
Journal:  AIDS       Date:  2010-06-01       Impact factor: 4.177

4.  Zidovudine, trimethoprim, and dapsone pharmacokinetic interactions in patients with human immunodeficiency virus infection.

Authors:  B L Lee; S Safrin; V Makrides; J G Gambertoglio
Journal:  Antimicrob Agents Chemother       Date:  1996-05       Impact factor: 5.191

5.  Neopterin and alpha and beta interleukin-1 levels in sera of patients with human immunodeficiency virus infection.

Authors:  M M Reddy; M H Grieco
Journal:  J Clin Microbiol       Date:  1989-09       Impact factor: 5.948

6.  Beta 2-microglobulin and neopterin: predictive markers for human immunodeficiency virus type 1 infection in children?

Authors:  M M Chan; J M Campos; S Josephs; N Rifai
Journal:  J Clin Microbiol       Date:  1990-10       Impact factor: 5.948

7.  High plasma level of soluble tumor necrosis factor receptor type II (sTNFRII) in asymptomatic HIV-1-infected patients.

Authors:  D Hober; S Benyoucef; A S Delannoy; D de Groote; F Ajana; Y Mouton; P Wattré
Journal:  Infection       Date:  1996 May-Jun       Impact factor: 3.553

8.  Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide.

Authors:  J R Munis; D D Richman; R S Kornbluth
Journal:  J Clin Invest       Date:  1990-02       Impact factor: 14.808

9.  Interleukin 1 induces HIV-1 expression in chronically infected U1 cells: blockade by interleukin 1 receptor antagonist and tumor necrosis factor binding protein type 1.

Authors:  E V Granowitz; B M Saget; M Z Wang; C A Dinarello; P R Skolnik
Journal:  Mol Med       Date:  1995-09       Impact factor: 6.354

10.  Transactivation of human immunodeficiency virus type 1 long terminal repeats by cell surface tumor necrosis factor alpha.

Authors:  W Tadmori; D Mondal; I Tadmori; O Prakash
Journal:  J Virol       Date:  1991-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.